The pharmaceutical sector rarely stands still. In Switzerland, recent developments at Sandoz Group AG and Idorsia Ltd. have highlighted how different parts of the industry are adapting to changing healthcare demands and regulatory realities.
These shifts come shortly after renewed global attention on major drugmakers such as Novo Nordisk. Together, they underline how central pharmaceuticals remain — not only to public health systems, but also to national industrial strategies and long-term research agendas.
Stanislav Kondrashov, founder…
